Skip to content
Screener

Eikon Therapeutics, Inc. EIKN Finance Lease Liabilities

Finance Lease Liabilities at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$213K—
Incyte logo
IncyteINCY
$28.42M-10.5%

Other financials

Income statement

See full
Operating income-$87.3M-22.3%
Net income-$83.0M-21.6%
EPS (diluted)-$2.46+90.9%

Balance sheet

See full
Cash & equivalents$161.2M-21.2%
Total debt$254.8M—
Total equity$550.7M+186%
Total assets$850.8M—

Cash flow

See full
Operating cash flow-$89.8M-64.7%
CapEx$262.0K-98.8%
Free cash flow-$90.1M-17.1%

Valuation

See full
Market cap$498.62M-36.3%
Enterprise value$592.29M—

Returns & leverage

See full
Debt / equity0.5×—
Current ratio11.8×—

Where this comes from

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:FinanceLeaseLiability.

The source filing: Eikon Therapeutics, Inc.’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216791

The Company did not have any finance leases as of March 31, 2026 and December 31, 2025.

Item 1. Condensed Financial Statements (Unaudited).

FAQ

What is Eikon Therapeutics, Inc.'s finance lease liabilities?
Eikon Therapeutics, Inc. (EIKN) reported finance lease liabilities of $0 in Q1 2026.
What does finance lease liabilities mean?
Present value of future payments on leases classified as finance leases under ASC 842 — treated similarly to debt on the balance sheet.

Ask your AI about Eikon Therapeutics, Inc.'s finance lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude